期刊文献+

奥马珠单抗治疗过敏性疾病及其相关进展 被引量:5

原文传递
导出
摘要 目的:归纳IgE单克隆抗体——奥马珠单抗在过敏性疾病治疗中的应用进展,同时介绍阻断IgE信号转导以治疗过敏性疾病的研究新进展。方法:查阅美国国立生物技术信息中心(NCBI)和相关专业学术期刊全文数据库1993-2013年有关奥马珠单抗以及阻断IgE信号转导以治疗过敏性疾病的研究文献,对相关研究进展作一整理归纳。结果与结论:奥马珠单抗抑制IgE和相关变应原介导的免疫反应,在哮喘、变应性鼻炎、过敏性皮肤疾病等过敏性疾病治疗中发挥了良好作用,具有良好的应用前景。通过阻断IgE信号转导以治疗过敏性疾病的策略也值得期待。
出处 《中国药房》 CAS CSCD 2014年第22期2083-2085,共3页 China Pharmacy
  • 相关文献

参考文献16

  • 1刘长智,郑晓滨,刘茂,等.奥马珠单抗治疗难治性哮喘疗效与安全性的Meta分析[J].中华临床医师杂志:电子版,2013.7(14):6519.
  • 2麦琳,孙蓉菲,李为民.奥马佐单抗治疗过敏性支气管哮喘疗效与安全性的系统评价[J].中国循证医学杂志,2013,13(6):709-716. 被引量:3
  • 3Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma[J]. J Allergy Clin lmmunol, 2009,124(6) : 1 210.
  • 4Busse WW, Morgan WJ, Gergen P J, et al. Randomized tri- al of omalizumab (anti-IgE) for asthma in inner-city chil- dren[J]. NEnglJMed, 2011,364(11) : 1 005.
  • 5Hanania NA, Alpan O, Hamilos DL, et al.Omalizumab in severe allergic asthma inadequately controlled with stan- dard therapy: a randomized trial[J].Ann lntern Med, 2011, 154(9):573.
  • 6Casale TB, Condemi J, LaForce C, et al. Effect of omali- zumab on symptoms of seasonal allergic rhinitis: a ran- domized controlled trial[J]. JAM_A, 2001,286(23) :2 956.
  • 7Chervinsky P, Casale T, Townley R, et aL Omalizumab, an anti-IgE antibody,, in the treatment of adults and ado- lescents with perennial allergic rhinitis[J]. Ann Allergy Asthma lmmunol, 2003,91 ( 2 ) : 160.
  • 8Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria[J]. Ann Allergy Asthma lmmunol, 2007, 99(2):190.
  • 9Kaplan AP, Joseph K, Maykut ILl, et al. Treatment of chron- ic autoimmune urticaria with omalizumab[J]. J Allergy Clin Immunol, 2008,122 ( 3 ) : 569.
  • 10Maurer M, Ros6n K, Hsieh H J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticar- ia[J]. NEnglJMed, 2013,368(10) :924.

二级参考文献38

  • 1GINA report, global strategy for asthma management and preven- tion. www.ginasthma.com, 2010. Accessed February 25, 2012.
  • 2Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Issued 1995 (NIH pub no. 02-3659); Accessed December 2011.
  • 3Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. ] Allergy Clin lmmunol, 2003, 111 (2): $486-494.
  • 4Chanez P, Contin-Bordes Cc, Garcia G, et al. Omalizumab-induced decrease of FceRI expression in patients with severe allergic asthma. RespirMed, 2010, 104(11): 1608-1617.
  • 5Higgins JPT, Green S (editors). Cochrane Handbook for System-atic Reviews of Interventions Version 5.0.1 [updated March 2011]. The Cochrane Collaboration, 2011.
  • 6Available from: http://www. cochrane-handbook.org.
  • 7Soler M, Matz J, Townley R, et al. The anti-IgE antibody omali- zumab reduces exacerbations and steroid requirement in allergic asthmatics. Official Journal of the European Society for Clinical Res- piratory Physiology, 2001, 18(2): 254-261.
  • 8Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recom- binant humanized monoclonal antibody, for the treatment of severe allergic asthma. The Journal of Allergy and Clinical Immunology, 2001, 108(2): 184-190.
  • 9Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglohulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy, 2004, 34(4): 632-638.
  • 10Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy, 2004, 59(7): 701-708.

共引文献2

同被引文献40

  • 1韩德民,张罗,黄丹,武阳丰,董震,许庚,孔维佳,暴继敏,周兵,汪审清,王德辉,王秋萍.我国11个城市变应性鼻炎自报患病率调查[J].中华耳鼻咽喉头颈外科杂志,2007,42(5):378-384. 被引量:402
  • 2陈灏珠,丁训杰,廖履坦,等.实用内科学[M].北京:人民卫生出版社,2013:1556.
  • 3刘长智,郑晓滨,刘茂,等.奥马珠单抗治疗难治性哮喘疗效与安全性的Meta分析.中华临床医师杂志(电子版),2013,7:6519-6525.
  • 4Kulthanan K, Jiamton S ,Thumpimukvatana N, et al. Chronic idiopathic urticaria : prevalence and clinical course[J]. J Dermatol, 2007,34 (5) : 294-301.
  • 5Saini SS. Chronic spontaneous urticaria:etiology and pathogenesis[J]. Immunol Allergy Clin North Am,2014, 34( 1 ) :33-52.
  • 6Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in pa- tients with refractory chronic urticaria[J]. Allergy Asthma Immunol Res, 2012,4(6) :357-361.
  • 7Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. AGA2 LEN task force report[J]. Allergy,2011, 66(3) :317-330.
  • 8Francrs L,Leiva-Salinas M ,Silvestre JF. Omalizumab in the treatment of chronic urticaria[J]. Actas Derrnosifiliogr, 2014,105 (1) :45-52.
  • 9Lefevre AC ,Deleuran M ,Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria[J]. Ann Dermatol, 2013,25 (2) :242-245.
  • 10Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab[J]. Clin Exp Allergy, 2009,39 (6) : 788-797.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部